November 2013

Anaxsys Announces an Independent Pilot Swiss Study in Colonoscopy Recommends the use of respiR8™ Continuous Respiratory Rate Counter
Breath monitoring with respiR8 is a practical and accurate method of measuring ventilation for patients undergoing endoscopic procedures under sedation
“Send, UK, November 12, 2013 - Anaxsys Ltd, the medical device company developing innovative respiratory devices, today announced that an independent Swiss study ‘ Breath monitoring with a new Respiratory Rate Monitoring Device during Colonoscopy : A pilot study’ recommends the use of respiR8™ continuous respiratory rate counter in colonoscopy procedures.”
Read more>>

July 2012

ANAXSYS FILES 510(K) FOR RESPIR8™ CONTINUOUS RESPIRATORY RATE COUNTER
Approval by FDA would provide U.S. Healthcare Professionals the potential for improved patient mortality in peri-operative environments
“The filing of the 510(k) for Anaxsys is an important milestone as it will facilitate the Company’s growth strategy and make respiR8 available to one of the largest healthcare markets – the United States,”
Read more>>

April 2011

EVERY BREATH YOU TAKE...
New monitor can give vital advance warning of cardiac arrest
A revolutionary medical monitoring device which could detect a heart attack up to 45 minutes before it occurs in a hospital patient has received a European seal of approval. 
Read more>>

October 2010

Anaxsys Announces Availability of respiR8 – World’s First Continuous Electrochemical Respiratory Rate Counter

respiR8 Provides Early Indication of Patient Deterioration and Potential for Improved Patient Outcomes

Send, UK, October 13, 2010 --- Anaxsys Ltd, the medical device company developing innovative respiratory devices, announced today the availability of respiR8 - the world’s first continuous electrochemical respiratory rate counter. Targeted at perioperative environments, respiR8 is an accurate, simple to use and cost effective means for enabling early detection of patient deterioration and providing improved patient outcomes.
Read more>>

September 2010

Anaxsys Secures £1 Million Funding to Commercialise Patented Sensor Technology in Respiratory Devices

Anaxsys announces its Respiratory Rate Counter Has Received CE Mark Approval

Send, UK, September 30, 2010 --- Anaxsys, the medical device company developing innovative respiratory devices, announced today that it has secured £1 million additional investment to accelerate the commercialisation of novel respiratory devices based on its patented sensor technology. Anaxsys further announced it has received CE Mark approval for respiR8 - the world’s first continuous electrochemical respiratory rate counter.
Read more>>